Search by Drug Name or NDC
NDC 42571-0381-01 CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE 5; 2.5 mg/1; mg/1 Details
CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE 5; 2.5 mg/1; mg/1
CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Micro Labs Limited. The primary component is CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE.
MedlinePlus Drug Summary
The combination of chlordiazepoxide and clidinium is used along with other medications to treat peptic ulcers, irritable bowel syndrome (IBS; a condition that causes stomach pain, bloating, constipation, and diarrhea), and enterocolitis (swelling in the intestines). Chlordiazepoxide is in a class of medications called benzodiazepines. It works by decreasing abnormal electrical activity in the brain. Clidinium is in a class of medications called anticholinergics. It helps to decrease stomach spasms and cramps.
Related Packages: 42571-0381-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Chlordiazepoxide and Clidinium
Product Information
| NDC | 42571-0381 |
|---|---|
| Product ID | 42571-381_fa3753a6-a410-6ae8-e053-6394a90a0106 |
| Associated GPIs | |
| GCN Sequence Number | 004902 |
| GCN Sequence Number Description | chlordiazepoxide/clidinium Br CAPSULE 5 MG-2.5MG ORAL |
| HIC3 | J2B |
| HIC3 Description | ANTICHOLINERGICS,QUATERNARY AMMONIUM |
| GCN | 74801 |
| HICL Sequence Number | 002037 |
| HICL Sequence Number Description | CHLORDIAZEPOXIDE/CLIDINIUM BROMIDE |
| Brand/Generic | Generic |
| Proprietary Name | CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 5; 2.5 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE |
| Labeler Name | Micro Labs Limited |
| Pharmaceutical Class | Anticholinergic [EPC], Benzodiazepine [EPC], Benzodiazepines [CS], Cholinergic Antagonists [MoA], Decreased Parasympathetic Acetylcholine Activity [PE], Digestive/GI System Activity Alteration [PE], GI Motility Alteration [PE] |
| DEA Schedule | CIV |
| Marketing Category | ANDA |
| Application Number | ANDA215835 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 42571-0381-01 (42571038101)
| NDC Package Code | 42571-381-01 |
|---|---|
| Billing NDC | 42571038101 |
| Package | 100 CAPSULE in 1 BOTTLE (42571-381-01) |
| Marketing Start Date | 2022-10-01 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.37339 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | CHLORDIAZEPOXIDE-CLIDINIUM CAP |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis